Mymetics Corp (MYMX)

[bow-tie]

The Baylor and BBI joint efforts are developing prototype subunit vaccines comprised of the SARS and MERS CoV spike proteins, which are the minimal receptor-binding domains, required for binding to the functional viral receptors in humans, Petrin said. He noted that the latest studies in mice with an optimized vaccine/adjuvant formulation have shown 100 percent efficacy with no detectable lung immunopathology, unlike prior attempts at vaccines with toxicity exceeding the risk of the disease itself.
https://www.prnewswire.com/news-releases/brighton-biotech-inc-acquires-exclusive-global-license-for-development-commercialization-of-vaccines-for-mers-sars-300161594.html